Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mesenchymal stromal cells (MSCs) are multipotent progenitor cells being investigated by Guangdong Provincial People's Hospital for the treatment of chronic graft-versus-host disease (cGvHD). These cells possess significant immunomodulatory properties, capable of suppressing the activation and proliferation of various immune cells, including T-cells, B-cells, and natural killer cells, while promoting the expansion of regulatory T-cells. In clinical trials, these MSCs are administered intravenously as an adjunct to standard immunosuppressive regimens (such as prednisone and calcineurin inhibitors) to improve response rates and outcomes in patients with newly diagnosed or steroid-refractory cGvHD. The therapy is currently being evaluated in a Phase 3 randomized study in Southern China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mesenchymal stromal cells (Guangdong Provincial People's Hospital).